

## **ATANIS Biotech AG completes capital increase and takes the next step towards clinical allergy diagnosis**

Bern, Switzerland - March 28, 2023 - ATANIS Biotech AG, a Swiss biotechnology company specializing in functional allergy diagnosis, today announced the successful completion of a significant capital increase. iXLife a venture capital fund from France co-led the round with US-based AllerFund, the first and only venture capital firm focused on social impact in the food allergy space. Additional investments came from experienced private biotech investors.

With proceeds from the financing, ATANIS will accelerate its product development, scale its services for pharma/biotech customers, and implement its go-to-market strategy.

“At ATANIS, our mission is to revolutionize the way allergies are diagnosed and thereby improve treatment success and quality of life for patients,” said Chief Executive Officer Jean-Pierre Kinet, M.D. “With this funding, we look forward to taking the next steps towards bringing our products to the market and making them available to clinicians.”

ATANIS is developing its FAST-PASE® technology, offering lab testing solutions to mimic allergic reactions safely in a test tube. Currently, the company is mainly serving customers with needs in preclinical drug development and QC testing. In March, ATANIS moved its operational premises to a new location in Bern enabling the company to increase its sample processing capacity. Additionally, three new team members were appointed, bolstering their commercialization capabilities: Doris Corpataux will lead the company’s regulatory strategy, Nathan Laborde will be responsible for implementing quality processes, and Bertrand Landel will spearhead commercial and marketing operations.

### **About ATANIS Biotech AG:**

The company was founded in 2021 as a spin-out of the University of Bern by Noemi Bachmeier-Zbären, Jean-Pierre Kinet, Thomas Kaufmann and Alexander Eggel to simplify and improve the current standard of care for the diagnosis of allergies. Together, the founders have over 70 years of combined experience in basic and clinical allergy research, cell and molecular biology and diagnostic assay development, and have published over 250 publications in high-impact journals. In recognition of its impact, ATANIS won 1<sup>st</sup> place in 2022 in the Stage-Up competition in Switzerland.

### **Contact:**

#### For Investor Inquiries:

Jean-Pierre Kinet, CEO  
Oberkirch, Switzerland  
Email: [jp.kinet@atanis-biotech.com](mailto:jp.kinet@atanis-biotech.com)

#### For Media Inquiries:

Noemi Zbären-Bachmeier, CTO & Managing Director  
Bern, Switzerland  
Email: [info@atanis-biotech.com](mailto:info@atanis-biotech.com)

Website: <https://www.atanis-biotech.com>

LinkedIn: <https://www.linkedin.com/company/atanis-biotech/>